In Post-Theranos Era, Epi One’s Transparent Approach to Cancer Detection Wins Investor Trust
Epi One’s proprietary genomic technology achieves 95% accuracy in preliminary tests, offering hope for earlier, more affordable cancer detection.New York, NY, Oct. 04, 2024 (GLOBE NEWSWIRE) — In a …